女性性功能障碍治疗市场规模、份额及成长分析（按药物、疾病、给药途径、分销管道和地区）－2025-2032 年产业预测

2023 年全球女性性功能障碍治疗市场规模为 4.805 亿美元，预计将从 2024 年的 5.4297 亿美元增长到 2032 年的 14.4344 亿美元，预测期内（2025-2032 年）的复合年增长率为 13%。

随着女性对性健康的认识不断提高以及寻求医疗干预的意愿不断增强，女性性功能障碍 (FSD) 治疗市场正在经历显着增长。随着社会规范的发展以及围绕女性性行为的讨论变得更加开放，围绕这些问题的耻辱感逐渐消失，为创新治疗铺平了道路。市场驱动因素包括女性人口老化，尤其是面临荷尔蒙相关功能障碍的停经后妇女。各种荷尔蒙疗法和非荷尔蒙疗法疗法的出现，加上个人化医疗和远端医疗的进步，正在改善治疗的机会。儘管有这些正面趋势，但挑战依然存在，包括文化禁忌、药品核准限制和监管障碍。然而，正在进行的临床研究和对教育和创新的日益关注强烈表明未来市场扩张的潜力。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 临床试验
• 管道分析

女性性功能障碍治疗市场规模（依药物类型）

• 市场概览
• 氟班色林
• 布美拉诺胜肽
• 奥司哌米芬
• 雌激素治疗
• 其他的

女性性功能障碍治疗市场规模（依疾病）

• 市场概览
• 性慾低下障碍（HSDD）
• 性交时疼痛
• 其他的

女性性功能障碍治疗市场规模（依给药途径）

• 市场概览
• 口服
• 肠外
• 局部的

女性性功能障碍治疗市场规模（依分销管道）

• 市场概览
• 医院药房
• 药局和药房
• 网路药局

女性性功能障碍治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Millendo Therapeutics（Tempest Therapeutics）
• AbbVie
• TherapeuticsMD
• Sorrento Therapeutics
• Palatin Technologies
• Eureka Therapeutics
• HRA Pharma
• NantKwest
• Bristol-Myers Squibb
• Pfizer
• Allergen
• Bayer
• Neurotrope
• AMAG Pharmaceuticals
• Sprout Pharmaceuticals, Inc.（US）
• Mayne Pharma Group Limited（Australia）
• Millicent Pharma Ltd.（Endoceutics, Inc.）（Ireland）
• Duchesnay Pharmaceutical Group Inc.（Canada）
• Freya Pharma Solutions BV（Netherlands）
• Acerus Pharmaceuticals Corporation（Canada）

结论和建议

Global Female Sexual Dysfunction Treatment Market size was valued at USD 480.5 Million in 2023 and is poised to grow from USD 542.97 Million in 2024 to USD 1443.44 Million by 2032, growing at a CAGR of 13% during the forecast period (2025-2032).

The female sexual dysfunction (FSD) treatment market is witnessing significant growth, driven by rising awareness of sexual health and an increased willingness among women to seek medical interventions. As societal norms evolve and discussions around female sexuality become more open, stigma surrounding these issues diminishes, paving the way for innovative treatments. Key market drivers include an aging female population, particularly postmenopausal women facing hormonal-related dysfunction. The availability of diverse hormonal and non-hormonal therapies, coupled with advancements in personalized medicine and telemedicine, enhances access to treatment. Despite these positive trends, challenges like cultural taboos, limited medication approvals, and regulatory hurdles persist. However, ongoing clinical research and a growing focus on education and innovation signal strong potential for future market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Female Sexual Dysfunction Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Female Sexual Dysfunction Treatment Market Segments Analysis

The global Female Sexual Dysfunction (FSD) Treatment market is segmented by drug, disorder, route of administration, and distribution channel. Key drugs include Flibanserin, Bremelanotide, Ospemifene, and Estrogen Therapy, with hormonal and non-hormonal therapies gaining traction. Major disorders treated are Hypoactive Sexual Desire Disorder (HSDD) and Dyspareunia. Oral administration leads due to convenience, while topical and parenteral options are growing. Distribution channels include hospital, retail, and online pharmacies, with online platforms expanding rapidly. North America dominates the market, while Asia Pacific shows strong growth driven by rising awareness, digital health adoption, and improved access to treatments across emerging healthcare systems.

Driver of the Global Female Sexual Dysfunction Treatment Market

The demand for treatment of Female Sexual Dysfunction (FSD) is being significantly driven by the growing awareness surrounding women's health issues and the increasing incidence of related conditions, such as symptoms associated with menopause, hormonal imbalances, and dysfunctions stemming from stress. The impact of contemporary lifestyles has led to heightened physical and mental health challenges, prompting healthcare systems and providers to incorporate FSD treatments into comprehensive wellness and preventive care strategies. This trend is especially prominent in areas like corporate wellness, reproductive health, and gynecology, where prioritizing sexual health is recognized as essential for enhancing overall quality of life and ensuring long-term well-being.

Restraints in the Global Female Sexual Dysfunction Treatment Market

The Global Female Sexual Dysfunction (FSD) Treatment market faces notable challenges due to high costs associated with specialist consultations, diagnostic tests, and prescribed medications, many of which insurance plans do not cover. This financial burden is especially pronounced for hormonal therapies, branded medications, and long-term treatment options, creating significant obstacles for patients, particularly in low- and middle-income areas. These cost-related issues can dramatically restrict access to necessary care, discouraging many women from pursuing treatment, which ultimately hinders broader acceptance and growth within the market. Addressing these financial barriers is crucial for improving access to FSD therapies.

Market Trends of the Global Female Sexual Dysfunction Treatment Market

The Global Female Sexual Dysfunction (FSD) Treatment market is witnessing a notable trend towards the integration of telehealth and digital therapeutics. This shift addresses the growing demand for discreet, convenient access to consultations, therapies, and prescriptions, thus overcoming geographic limitations and societal stigma often associated with sexual health issues. The appeal of virtual care aligns with patient expectations for privacy and flexibility, enabling continuous monitoring of treatment progress and personalized adjustments in real-time. As healthcare technology advances, it is anticipated that this trend will further enhance patient engagement and satisfaction, ultimately driving the growth of the FSD treatment market globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Clinical Trial
• Pipeline Analysis

Global Female Sexual Dysfunction Treatment Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Flibanserin
• Bremelanotide
• Ospemifene
• Estrogen Therapy
• Others

Global Female Sexual Dysfunction Treatment Market Size by Disorder & CAGR (2025-2032)

• Market Overview
• Hypoactive Sexual Desire Disorder (HSDD)
• Dyspareunia
• Others

Global Female Sexual Dysfunction Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Topical

Global Female Sexual Dysfunction Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Female Sexual Dysfunction Treatment Market Size & CAGR (2025-2032)

• North America (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • US
  • Canada
• Europe (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Millendo Therapeutics (Tempest Therapeutics)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TherapeuticsMD
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Palatin Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eureka Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRA Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotrope
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMAG Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sprout Pharmaceuticals, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Millicent Pharma Ltd. (Endoceutics, Inc.) (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Duchesnay Pharmaceutical Group Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freya Pharma Solutions B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acerus Pharmaceuticals Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations